Dade Behring and Third Wave sign icensing deal:
This article was originally published in Clinica
Dade Behring and Third Wave Technologies have formed a non-exclusive, royalty-bearing, cross-licensing agreement. As a result, Dade has the right to develop in vitro diagnostic tests for blood clotting disorders and to detect drug resistant infectious diseases organisms based on Third Wave's Invader patents. Dade has granted Third Wave freedom to operate under certain of its patents. Invader assays have a high level of specificity, simplicity and cost effectiveness, the companies claim. In addition, they do not have the carryover contamination complications associated with PCR, they maintain.